Drug Profile
Candida vaccine Sap2 - NovaDigm Therapeutics
Alternative Names: PEV7; PEV7A; PEV7BLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Istituto Superiore di Sanita
- Developer NovaDigm Therapeutics
- Class Fungal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Vulvovaginal candidiasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Vulvovaginal-candidiasis in Switzerland (IM, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Vulvovaginal-candidiasis in Switzerland (Vaginal, Pessary)
- 10 Jun 2014 NovaDigm Therapeutics acquires the rights to Candida vaccine (Sap2 antigen) from Pevion Biotech and Istituto Superiore di Sanita